Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.

Rona hopes technology acquired from Sanofi will enhance its RNA capabilities in liver and non-liver indications. NeuroFront gets Greater China and Singapore rights to Novaremed’s neuropathic pain drug.

Looking back at recent company decisions to shift product strategy, restructure its US Upsher-Smith business and acquire manufacturing sites from a former domestic competitor, Sawai's president shares the breadth of the Japanese firm’s vision.

Kenzo Sawai, president of Japanese generics giant Sawai Pharmaceutical, talks about the firm’s strategy and backstory of efforts to maintain product supplies amid the country’s ongoing generic crisis in an exclusive interview. He also urges Japan to take "the best and only chance" to reform its drug pricing system to help the entire market survive.